JP2017165783A - 脂質異常症の治療用のチョウセンアザミの抽出物 - Google Patents
脂質異常症の治療用のチョウセンアザミの抽出物 Download PDFInfo
- Publication number
- JP2017165783A JP2017165783A JP2017129373A JP2017129373A JP2017165783A JP 2017165783 A JP2017165783 A JP 2017165783A JP 2017129373 A JP2017129373 A JP 2017129373A JP 2017129373 A JP2017129373 A JP 2017129373A JP 2017165783 A JP2017165783 A JP 2017165783A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- content
- treatment
- extract according
- dyslipidemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000284 extract Substances 0.000 title claims abstract description 46
- 238000011282 treatment Methods 0.000 title claims abstract description 12
- 208000032928 Dyslipidaemia Diseases 0.000 title claims abstract description 6
- 208000017170 Lipid metabolism disease Diseases 0.000 title claims abstract description 6
- 244000019459 Cynara cardunculus Species 0.000 title abstract description 3
- 235000019106 Cynara scolymus Nutrition 0.000 title abstract description 3
- 235000016520 artichoke thistle Nutrition 0.000 title abstract description 3
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- 229930003935 flavonoid Natural products 0.000 claims abstract description 10
- 235000017173 flavonoids Nutrition 0.000 claims abstract description 10
- CWVRJTMFETXNAD-GMZLATJGSA-N 5-Caffeoyl quinic acid Natural products O[C@H]1C[C@](O)(C[C@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-GMZLATJGSA-N 0.000 claims abstract description 9
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims abstract description 9
- 150000002215 flavonoids Chemical class 0.000 claims abstract description 9
- CWVRJTMFETXNAD-NXLLHMKUSA-N trans-5-O-caffeoyl-D-quinic acid Chemical compound O[C@H]1[C@H](O)C[C@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-NXLLHMKUSA-N 0.000 claims abstract description 9
- 241000132536 Cirsium Species 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 8
- 241000894007 species Species 0.000 claims description 6
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 235000011464 Pachycereus pringlei Nutrition 0.000 claims description 2
- 240000006939 Pachycereus weberi Species 0.000 claims description 2
- 235000011466 Pachycereus weberi Nutrition 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- KHSCYOFDKADJDJ-NQLMQOPMSA-N Cynaropicrin Chemical compound OCC(=C)C(=O)O[C@H]1CC(=C)[C@@H]2C[C@H](O)C(=C)[C@@H]2[C@H]2OC(=O)C(=C)[C@H]12 KHSCYOFDKADJDJ-NQLMQOPMSA-N 0.000 abstract description 2
- STQKFHDZSADKCG-UHFFFAOYSA-N cynaropicrin Natural products OC1CC2C(C3OC(=O)C(=C)C3C(CC2=C)OC(=O)C(=C)O)C1=C STQKFHDZSADKCG-UHFFFAOYSA-N 0.000 abstract description 2
- 241000208947 Cynara Species 0.000 abstract 1
- 235000003198 Cynara Nutrition 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 28
- 108010010234 HDL Lipoproteins Proteins 0.000 description 14
- 102000015779 HDL Lipoproteins Human genes 0.000 description 14
- 235000012000 cholesterol Nutrition 0.000 description 13
- 241000196324 Embryophyta Species 0.000 description 7
- 241000208296 Datura Species 0.000 description 5
- 239000002028 Biomass Substances 0.000 description 4
- 208000004930 Fatty Liver Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 206010019708 Hepatic steatosis Diseases 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 208000010706 fatty liver disease Diseases 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 231100000240 steatosis hepatitis Toxicity 0.000 description 4
- 208000035150 Hypercholesterolemia Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 238000008214 LDL Cholesterol Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000000575 pesticide Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 240000005250 Chrysanthemum indicum Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000001989 choleretic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002178 gastroprotective effect Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- -1 luteolin flavonoids Chemical class 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 238000009329 organic farming Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Nutrition Science (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pyrane Compounds (AREA)
- Furan Compounds (AREA)
Abstract
Description
本発明は、選択された栽培品種の葉から生産される高い含有率のフラボノイドとセスキテルペンを有する、チョウセンアザミの新規な抽出物の調製物に関する。本発明の抽出物は、HDLコレステロールを増加させ、そして、心臓血管にリスクを有する患者における脂質異常症の治療に有用である。また、脂肪と炭水化物のバランスを正常化するとともに、本発明の抽出物は、消化不良ならびに非アルコール依存性の脂肪肝の抑制にも有用である。特には、抽出物は、LDL/HDL比を良好に変化させることで、平均的な指標値を下回っている患者において、HDLコレステロール量の著しい増加をもたらす。
グローブ・アーティチョーク(チョウセンアザミ)の抽出物について、その胆汁分泌誘発(choleretic)作用、利胆(cholagogic)作用、消化不良防止(anti−dyspepsia)作用、ならびに、穏やかなコレステロール低減作用が知られており;そのコレステロール低減は、中程度(約10%を超えない)である。使用された抽出物の組成、ならびに、治療手順の有効性(quality)に関して、公表されている研究は相違している。
チョウセンアザミの抽出物の投与に続く、HDLコレステロールにおける中程度の不規則な増加は文献に報告されているが、その再現性ならびに整合性の証拠は付されていない。以下の研究(Natur. Med.,13、17-24、1998; Arzneim-Forschung, 50, 260-65, 2000, The Cochrane Library, 2002, Issue 3)は、実質的な関連性が低い相反するデータを報告している。
(1)30〜45%の含有率のカフェオイルキナ酸、8〜16%の含有率のフラボノイド、ならびに、10〜18%の含有率のシナロピクリンを含む、チョウセンアザミ属の種の品種の葉の抽出物。
(2)カフェオイルキナ酸の含有率は35±2%であり、フラボノイドの含有率は12±2%であり、ならびに、シナロピクリンの含有率は13±2%である、上記(1)に記載の抽出物。
(3)選別されたチョウセンアザミの栽培品種、あるいは、カルドンの栽培品種の若芽から得られる、上記(1)または(2)に記載の抽出物。
(4)チョウセンアザミの栽培品種から得られる、上記(3)に記載の抽出物。
(5)前記栽培品種は、有棘のムラサキ色の品種である、上記(4)に記載の抽出物。
(6)高血糖症、高コレステロール血症、高血圧症、ならびに、脂肪肝の薬理学的治療に使用するための、上記(1)乃至(5)のいずれかに記載の抽出物。
(7)HDLコレステロールの増加に使用するための、上記(1)乃至(5)のいずれかに記載の抽出物。
(8)HDL/HDL比を変化させてHLDコレステロールを増加させる、高コレステロール血症の治療に使用するための上記(1)乃至(5)のいずれかに記載の抽出物。
(9)少なくとも一つの付形剤または担体と混合した状態で、上記(1)乃至(5)のいずれかに記載の抽出物を活性成分として含有する医薬組成物。
(10)担体は、ω−3不飽和脂肪酸を含有する油である、上記(9)に記載の組成物。
以上の通り、前記抽出物は、高血糖症、高コレステロール血症、高血圧症または脂肪肝の薬理学的な予防及び/または治療に使用することができる。
Claims (11)
- 30〜45%の含有率のカフェオイルキナ酸、8〜16%の含有率のフラボノイド、ならびに、13±2%の含有率のシナロピクリンを含む、チョウセンアザミ属の種の品種の葉の抽出物。
- カフェオイルキナ酸の含有率は35±2%であり、フラボノイドの含有率は12±2%である、請求項1に記載の抽出物。
- 選別されたチョウセンアザミの栽培品種、あるいは、カルドンの栽培品種の若芽から得られる、請求項1または2に記載の抽出物。
- チョウセンアザミの栽培品種から得られる、請求項3に記載の抽出物。
- 前記栽培品種は、有棘のムラサキ色の品種である、請求項4に記載の抽出物。
- メタボリックシンドロームの治療に使用するための、請求項1〜5に記載の抽出物。
- 心臓血管にリスクを有する患者における脂質異常症の治療に使用するための、請求項1〜5に記載の抽出物。
- 少なくとも一つの付形剤または担体と混合した状態で、請求項1〜5のいずれか1項に記載の抽出物を活性成分として含有する医薬組成物。
- 担体は、ω−3不飽和脂肪酸を含有する油である、請求項8に記載の組成物。
- メタボリックシンドロームの治療用の薬剤の製造のための、請求項1〜5のいずれか1項に記載のメタボリックシンドロームの治療のための有効成分としての使用方法。
- 心臓血管にリスクを有する患者における脂質異常症の治療用の薬剤の製造のための、請求項1〜5のいずれか1項に記載の心臓血管にリスクを有する患者における脂質異常症の治療のための有効成分としての使用方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT001670A ITMI20111670A1 (it) | 2011-09-16 | 2011-09-16 | Estratti di cynara scolimus per il trattamento di dislipidemie |
ITMI2011A001670 | 2011-09-16 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014530201A Division JP2014526486A (ja) | 2011-09-16 | 2012-09-13 | 脂質異常症の治療用のチョウセンアザミの抽出物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017165783A true JP2017165783A (ja) | 2017-09-21 |
JP6335373B2 JP6335373B2 (ja) | 2018-05-30 |
Family
ID=44907959
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014530201A Pending JP2014526486A (ja) | 2011-09-16 | 2012-09-13 | 脂質異常症の治療用のチョウセンアザミの抽出物 |
JP2017129373A Expired - Fee Related JP6335373B2 (ja) | 2011-09-16 | 2017-06-30 | 脂質異常症の治療用のチョウセンアザミの抽出物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014530201A Pending JP2014526486A (ja) | 2011-09-16 | 2012-09-13 | 脂質異常症の治療用のチョウセンアザミの抽出物 |
Country Status (22)
Country | Link |
---|---|
US (1) | US9687468B2 (ja) |
EP (1) | EP2755669B1 (ja) |
JP (2) | JP2014526486A (ja) |
KR (1) | KR102026993B1 (ja) |
CN (2) | CN111184754A (ja) |
AR (1) | AR087878A1 (ja) |
AU (1) | AU2012307404B2 (ja) |
BR (1) | BR112014004532B1 (ja) |
CA (1) | CA2845708C (ja) |
CL (1) | CL2014000595A1 (ja) |
ES (1) | ES2629186T3 (ja) |
HK (1) | HK1198935A1 (ja) |
HU (1) | HUE035035T2 (ja) |
IL (1) | IL231497B (ja) |
IT (1) | ITMI20111670A1 (ja) |
MX (1) | MX349587B (ja) |
PL (1) | PL2755669T3 (ja) |
PT (1) | PT2755669T (ja) |
RU (1) | RU2608459C2 (ja) |
SG (1) | SG11201400618XA (ja) |
SI (1) | SI2755669T1 (ja) |
WO (1) | WO2013037857A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20121570A1 (it) * | 2012-09-20 | 2014-03-21 | Indena Spa | Nuovi estratti di cynara scolimus, coffea spp. e olea europaea per il trattamento della sindrome metabolica |
FR3042413B1 (fr) * | 2015-10-20 | 2019-07-12 | Valbiotis | Composition comprenant un melange de molecules extraites de chrysanthellum indicum et de cynara scolymus et utilisation pour agir sur le metabolisme glucidique et/ou lipidique |
CN108142881A (zh) * | 2018-03-20 | 2018-06-12 | 爱可道生物科技有限公司 | 一种洋蓟花蕾提取物降血压胶囊制品及其生产工艺 |
WO2021220050A1 (en) * | 2020-05-01 | 2021-11-04 | Health And Happiness (H&H) Hong Kong Limited | New compositions useful for treating elevated blood lipid levels |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004537578A (ja) * | 2001-08-08 | 2004-12-16 | リヒトヴァー,ファルマ アーゲー | アーティチョーク葉抽出物 |
WO2008107183A1 (en) * | 2007-03-07 | 2008-09-12 | Indena S.P.A. | Cynara scolymus extracts and compositions containing them |
JP2009501708A (ja) * | 2005-07-14 | 2009-01-22 | インデナ・ソチエタ・ペル・アチオニ | チョウセンアザミ抽出物、その使用及びそれを含む配合物 |
WO2010083968A1 (en) * | 2009-01-20 | 2010-07-29 | Indena S.P.A. | Compositions comprising a lipophilic extract of zingiber officinale and an extract of cynara scolymus, which are useful for the prevention and treatment of oesophageal reflux and irritable bowel syndrome |
WO2011085979A1 (en) * | 2010-01-14 | 2011-07-21 | Intermed Discovery Gmbh | Use of tricyclic sesquiterpene lactones in the treatment of obesity and related diseases and non-therapeutic treatable conditions |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19627376A1 (de) * | 1996-07-06 | 1998-01-08 | Aar Pharma Adler Apotheke | Verwendung von Artischocken-(Cynara)-Extrakten |
EP0958828A1 (de) * | 1998-05-22 | 1999-11-24 | Greither, Peter | Präparat auf der Basis der Artischockenpflanze, insbesondere zur Verwendung als Arzneimittel oder Nahrungsergänzungsmittel |
US6162438A (en) * | 1999-06-24 | 2000-12-19 | Chromak Research, Inc. | Herbal compositions and their use as agents for control of hypertension, hypercholesterolemia and hyperlipidemia |
CN100496525C (zh) * | 2004-04-02 | 2009-06-10 | 李嫦梅 | 从洋蓟根、茎、叶中提取活性成份的方法及其应用 |
BRPI0808569A2 (pt) * | 2007-03-07 | 2014-09-02 | Indena Spa | Extratos de cynara scolymus e composições contendo a mesma |
US20080220096A1 (en) * | 2007-03-07 | 2008-09-11 | Indena S. P. A. | Cynara scolymus extracts and compositions containing them |
WO2009100970A1 (de) * | 2008-02-14 | 2009-08-20 | Swiss Caps Rechte Und Lizenzen Ag | Darreichungsform enthaltend zubereitungen aus solanum melongena und cynara scolymus |
-
2011
- 2011-09-16 IT IT001670A patent/ITMI20111670A1/it unknown
-
2012
- 2012-09-13 HU HUE12769052A patent/HUE035035T2/en unknown
- 2012-09-13 CN CN202010082048.7A patent/CN111184754A/zh active Pending
- 2012-09-13 ES ES12769052.7T patent/ES2629186T3/es active Active
- 2012-09-13 CA CA2845708A patent/CA2845708C/en active Active
- 2012-09-13 AU AU2012307404A patent/AU2012307404B2/en not_active Ceased
- 2012-09-13 SG SG11201400618XA patent/SG11201400618XA/en unknown
- 2012-09-13 PT PT127690527T patent/PT2755669T/pt unknown
- 2012-09-13 JP JP2014530201A patent/JP2014526486A/ja active Pending
- 2012-09-13 US US14/342,593 patent/US9687468B2/en active Active
- 2012-09-13 KR KR1020147006758A patent/KR102026993B1/ko active IP Right Grant
- 2012-09-13 SI SI201230953A patent/SI2755669T1/sl unknown
- 2012-09-13 PL PL12769052T patent/PL2755669T3/pl unknown
- 2012-09-13 RU RU2014109450A patent/RU2608459C2/ru active
- 2012-09-13 WO PCT/EP2012/067889 patent/WO2013037857A1/en active Application Filing
- 2012-09-13 CN CN201280044558.9A patent/CN103874498A/zh active Pending
- 2012-09-13 EP EP12769052.7A patent/EP2755669B1/en active Active
- 2012-09-13 BR BR112014004532-1A patent/BR112014004532B1/pt not_active IP Right Cessation
- 2012-09-13 MX MX2014003050A patent/MX349587B/es active IP Right Grant
- 2012-09-14 AR ARP120103396A patent/AR087878A1/es unknown
-
2014
- 2014-03-12 CL CL2014000595A patent/CL2014000595A1/es unknown
- 2014-03-13 IL IL231497A patent/IL231497B/en active IP Right Grant
- 2014-12-15 HK HK14112568.1A patent/HK1198935A1/xx unknown
-
2017
- 2017-06-30 JP JP2017129373A patent/JP6335373B2/ja not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004537578A (ja) * | 2001-08-08 | 2004-12-16 | リヒトヴァー,ファルマ アーゲー | アーティチョーク葉抽出物 |
JP2009501708A (ja) * | 2005-07-14 | 2009-01-22 | インデナ・ソチエタ・ペル・アチオニ | チョウセンアザミ抽出物、その使用及びそれを含む配合物 |
WO2008107183A1 (en) * | 2007-03-07 | 2008-09-12 | Indena S.P.A. | Cynara scolymus extracts and compositions containing them |
WO2010083968A1 (en) * | 2009-01-20 | 2010-07-29 | Indena S.P.A. | Compositions comprising a lipophilic extract of zingiber officinale and an extract of cynara scolymus, which are useful for the prevention and treatment of oesophageal reflux and irritable bowel syndrome |
WO2011085979A1 (en) * | 2010-01-14 | 2011-07-21 | Intermed Discovery Gmbh | Use of tricyclic sesquiterpene lactones in the treatment of obesity and related diseases and non-therapeutic treatable conditions |
Also Published As
Publication number | Publication date |
---|---|
HUE035035T2 (en) | 2018-05-02 |
AU2012307404A1 (en) | 2014-03-06 |
MX349587B (es) | 2017-08-03 |
RU2014109450A (ru) | 2015-10-27 |
BR112014004532B1 (pt) | 2022-02-22 |
US20140228428A1 (en) | 2014-08-14 |
CN111184754A (zh) | 2020-05-22 |
RU2608459C2 (ru) | 2017-01-18 |
SI2755669T1 (sl) | 2017-06-30 |
IL231497B (en) | 2019-07-31 |
AU2012307404B2 (en) | 2017-05-25 |
CN103874498A (zh) | 2014-06-18 |
AR087878A1 (es) | 2014-04-23 |
ITMI20111670A1 (it) | 2013-03-17 |
JP2014526486A (ja) | 2014-10-06 |
CA2845708A1 (en) | 2013-03-21 |
WO2013037857A1 (en) | 2013-03-21 |
PT2755669T (pt) | 2017-06-30 |
CA2845708C (en) | 2019-11-12 |
BR112014004532A2 (pt) | 2017-03-28 |
CL2014000595A1 (es) | 2014-11-14 |
MX2014003050A (es) | 2014-04-10 |
EP2755669A1 (en) | 2014-07-23 |
KR102026993B1 (ko) | 2019-09-30 |
PL2755669T3 (pl) | 2017-09-29 |
EP2755669B1 (en) | 2017-04-05 |
HK1198935A1 (en) | 2015-06-19 |
JP6335373B2 (ja) | 2018-05-30 |
US9687468B2 (en) | 2017-06-27 |
IL231497A0 (en) | 2014-04-30 |
ES2629186T3 (es) | 2017-08-07 |
SG11201400618XA (en) | 2014-05-29 |
KR20140067044A (ko) | 2014-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6335373B2 (ja) | 脂質異常症の治療用のチョウセンアザミの抽出物 | |
TW200904461A (en) | A pharmaceutical composition for treating depression and method for preparation thereof | |
MX2008014407A (es) | Composicion que comprende por lo menos un alcohol alifatico superior y un extracto de griffonia simplicifolia. | |
US10220065B2 (en) | Compositions comprising a lipophilic extract of zingiber officinale and an extract of cynara scolymus, which are useful for the prevention and treatment of oesophageal reflux and irritable bowel syndrome | |
JP6324391B2 (ja) | 肥満を治療および予防するための製剤 | |
Rodriguez Villanueva et al. | An insight into a blockbuster phytomedicine; Marrubium vulgare L. herb. More of a myth than a reality? | |
US10967027B2 (en) | Extracts of Cyclanthera pedata and formulations and uses thereof | |
Singhai et al. | The potential of natural products in the management of cardiovascular disease | |
Iqbal et al. | Antihyperlipidemic efficacy of cinnamon in albino rats | |
JP4601069B2 (ja) | 高脂血症治療のための相乗効果的医薬組成物 | |
Malhotra et al. | A Review on History, Chemical Constituents, Phytochemistry, Pharmacological Activities, and Recent Patents of Valerian | |
CN101375844A (zh) | 以丹酚酸b为原料的抗抑郁药物及其制法 | |
Frost | Herbal medicines and interactions with anesthetic agents | |
US11911431B2 (en) | Sustained release ashwagandha extract | |
CN105246472B (zh) | 含有鸟氨酸和/或门冬氨酸的组合物及其应用 | |
Bhaskarrao et al. | Novel antidiabetic polyherbal formulation for synergistic therapeutic effects in streptozotocin (stz)-induced diabetic rats | |
US20030059487A1 (en) | Composition and method for the treatment of hypercholesterolemia and hyperlipidemia in mammals | |
CN106265824B (zh) | 福建茶提取物在制备治疗高脂血症药物中的应用 | |
JP2005232084A (ja) | 血中脂肪降下剤とその製造方法、血中脂肪降下作用のある健康食品 | |
Team | How To Reverse Prediabetes? Top 10 Herbs That Are Ideal for Sugar Metabolism Prediabetes! | |
CN101810606A (zh) | 2-(6-羟基-2′,3′-二甲氧基苯基)-6-羟基-7-甲氧基苯骈呋喃在制备单胺氧化酶抑制剂中的应用 | |
IQBAL et al. | Kitchen Spices as Complementary and Alternative Medicine: Pharmacothera-peutic Potential and Challenges | |
Sinha | Hypolipidemic Effect of Aegle Marmelos on Hyperlipidemic Rat Models |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170728 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180403 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180427 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6335373 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |